The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.
 
Xinghua Lu
Employment - DeepRx
Leadership - DeepRx
Stock and Other Ownership Interests - DeepRx
 
Lujia Chen
No Relationships to Disclose
 
Ying Wang
No Relationships to Disclose
 
Chunhui Cai
No Relationships to Disclose
 
Rim S Kim
Employment - AstraZeneca/MedImmune
Leadership - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Corey Lipchik
No Relationships to Disclose
 
Debora Fumagalli
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Tesaro (Inst)
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Nicholas J. Petrelli
No Relationships to Disclose
 
Jennifer Marie Suga
No Relationships to Disclose
 
Judith O. Hopkins
No Relationships to Disclose
 
Naoyuki G. Saito
No Relationships to Disclose
 
Norman Wolmark
No Relationships to Disclose
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Honoraria - Schrodinger (I)
 
Min Sun
Leadership - DeepRx
Stock and Other Ownership Interests - DeepRx
Consulting or Advisory Role - MCG health
 
Katherine L. Pogue-Geile
Research Funding - NSABP Foundation (Inst)
Patents, Royalties, Other Intellectual Property - A signature has been developed and an agreement has been reached with a South Korean company for commercial use of the patent to begin soon. The title of the patent is "Composition for prognosis and neoadjuvant chemoradiotherapy response prediction of rec
Travel, Accommodations, Expenses - Pfizer